Published in Liver Transpl on October 01, 2011
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57
Liver transplantation for hepatocellular carcinoma: past, present and future. Middle East J Dig Dis (2013) 0.79
Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma: Brazilian Survey. Clinics (Sao Paulo) (2016) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell (2008) 6.48
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Oncogene addiction. Cancer Res (2008) 5.66
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
The cancer biomarker problem. Nature (2008) 4.64
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut (2008) 3.65
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol (2009) 3.43
Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology (2001) 2.73
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol (2009) 2.16
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology (2007) 1.81
Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer (2005) 1.73
Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg (2004) 1.62
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology (2005) 1.48
New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res (2010) 1.46
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol (2010) 1.36
Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci (2010) 1.00
Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol (2008) 0.88
Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein. Int J Oncol (1999) 0.85
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 10.25
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology (2014) 3.31
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology (2011) 3.00
Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet (2002) 2.85
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology (2014) 2.68
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Characterization of small solid tumors in the pancreas: the value of contrast-enhanced harmonic endoscopic ultrasonography. Am J Gastroenterol (2011) 2.49
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol (2013) 2.46
Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol (2012) 2.39
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol (2009) 2.31
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology (2009) 2.20
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas. Ultrasound Med Biol (2007) 2.00
Prospective comparative study of the EUS guided 25-gauge FNA needle with the 19-gauge Trucut needle and 22-gauge FNA needle in patients with solid pancreatic masses. J Gastroenterol Hepatol (2008) 1.98
Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med (2007) 1.97
EUS-guided broad plexus neurolysis over the superior mesenteric artery using a 25-gauge needle. Am J Gastroenterol (2010) 1.92
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology (2013) 1.81
Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology (2007) 1.81
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol (2010) 1.79
Genetics of hepatobiliary carcinogenesis. Semin Liver Dis (2011) 1.79
Imaging findings of biliary hamartomas. World J Gastroenterol (2005) 1.77
Anisakis in a biopsy specimen from the edge of a gastric ulcer: report of a case. Gastrointest Endosc (2004) 1.72
Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology (2012) 1.69
Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet (2007) 1.68
Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol (2007) 1.65
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology (2008) 1.58
A novel perfusion imaging technique of the pancreas: contrast-enhanced harmonic EUS (with video). Gastrointest Endosc (2008) 1.55
Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US. J Gastroenterol (2005) 1.53
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology (2012) 1.52
Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology (2005) 1.52
Identification and characterization of IgG4-associated autoimmune hepatitis. Liver Int (2009) 1.49
Consensus on extra-hepatic portal vein obstruction. Liver Int (2006) 1.47
Hepatic nodular lesions caused by abnormal hepatic circulation: etiological and clinical aspects. J Gastroenterol (2003) 1.47
Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab (2004) 1.46
Heat shock protein A4 controls cell migration and gastric ulcer healing. Dig Dis Sci (2015) 1.42
Signaling pathways governing tumor angiogenesis. Oncology (2011) 1.42
Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology (2012) 1.37
Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology (2013) 1.36
HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem (2007) 1.36
Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology (2010) 1.35
Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis (2011) 1.35
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist (2010) 1.34
Subtype classification of hepatocellular adenoma. Dig Surg (2010) 1.33
Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology (2005) 1.33
Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. Oncology (2011) 1.32
Radiofrequency ablation of hepatocellular carcinoma: Current status. World J Radiol (2010) 1.31
Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther (2011) 1.29
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology (2012) 1.29
Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology (2008) 1.28
CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur J Cancer (2011) 1.26
Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg (2014) 1.25
Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol (2012) 1.25
GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol (2011) 1.25
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res (2015) 1.23
Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology (2003) 1.22
Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Hum Mol Genet (2005) 1.22
Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis (2010) 1.21
Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol (2007) 1.21
Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome. AJR Am J Roentgenol (2004) 1.20
Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol (2012) 1.19
Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology (2008) 1.18
Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol (2011) 1.17
Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio. AJR Am J Roentgenol (2004) 1.17
Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology (2007) 1.17
Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int (2008) 1.17
Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology (2010) 1.15
Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol (2003) 1.15
Endoscopic ultrasound: contrast enhancement. Gastrointest Endosc Clin N Am (2012) 1.14
Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUS (with videos). Gastrointest Endosc (2011) 1.13
Radiofrequency ablation of hepatocellular carcinoma: a literature review. Int J Hepatol (2011) 1.13
Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes (2010) 1.13
Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography. AJR Am J Roentgenol (2003) 1.13
Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology (2008) 1.12
Hepatocellular adenoma: what is new in 2008. Hepatol Int (2008) 1.12
Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation. AJR Am J Roentgenol (2008) 1.12
Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res (2010) 1.11
Endoscopic ultrasonography-guided biliary drainage: evaluation of a choledochoduodenostomy technique. Pancreatology (2011) 1.11
Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol (2006) 1.11
Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Oncology (2007) 1.10
Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol (2009) 1.10
Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol (2011) 1.09
Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology (2007) 1.08
Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology (2010) 1.08